Detection of ultra-low concentrations of bromodihydrochlorophenylbenzodiazepine (phenazepam) and its metabolites in biological objects
- 25 March 2022
- journal article
- research article
- Published by Federal Medical Biological Agency
- No. 2022(1)
Abstract
In extreme situations, reliable detection of the minimum therapeutic concentrations of psychotropic substances is important, since this allows one to provide adequate resuscitation. The group of benzodiazepine derivatives, which includes bromodihydrochlorophenylbenzodiazepine (phenazepam), is widely used in clinical practice. Along with the positive clinical effect, phenazepam has numerous side effects, capable of causing poisoning, even death. The study was aimed to develop the method for detection of the phenazepam metabolites by high-resolution HPLC–TMS suitable for achieving the aims and objectives of forensic medical expertise in case of the ultra-low urine substance concentrations. Urine of six patients (males and females aged 28–40), who were prescribed phenazepam and took the drug at minimum therapeutic concentrations on an ad hoc basis, was used during the study. Optimum conditions for the analyte chromatography after the urine sample preparation were defined with the phenazepam retention time of 7.05 ± 0.06 min; specific ions (m/z) 179, 183, 206, 242, 271, 285, 320, 348 (main) were defined for identification of phenazepam.Keywords
This publication has 2 references indexed in Scilit:
- Liquid chromatography-high resolution-tandem mass spectrometry using Orbitrap technology for comprehensive screening to detect drugs and their metabolites in blood plasmaAnalytica Chimica Acta, 2017
- Orbitrap technology for comprehensive metabolite-based liquid chromatographic–high resolution-tandem mass spectrometric urine drug screening – Exemplified for cardiovascular drugsAnalytica Chimica Acta, 2015